GPR109 receptor agonist-1
Based on 1 Customer Validation
GPR109 receptor agonist-1 is a highly selective agonist of the human orphan G protein-coupled receptor GPR109b, and does not activate the mouse homologous receptor PUMA-G. GPR109 receptor agonist-1 functionally modulates the human GPR109b receptor via the cAMP signaling pathway, with an EC50 of 400 nM. GPR109 receptor agonist-1 inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors. GPR109 receptor agonist-1 can be used in studies related to dyslipidemia and atherosclerosis.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 306935-41-1
- Formula: C10H11N3O2
- Molecular Weight:205.22
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
pEC50: 6.40 ± 0.36 (GPR109b)[1]
GPR109 receptor agonist-1 (compound 3a) (30 pM-100 μM) completely reverses the cAMP elevation effect of Forskolin (HY-15371), and shows no significant activity against the highly homologous GPR109a receptor and non-transfected control cells at a concentration of 1 mM[1].
GPR109 receptor agonist-1 (1-100 nM) dose-dependently inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human cadaveric subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Freshly isolated human cadaver subcutaneous adipocytes
-
Concentration:1 nM to 100 nM
-
Incubation Time:/
-
Result:Dose-dependently inhibited isoproterenol-stimulated lipolysis, which was quantified by measuring glycerol release into the culture medium.
Exhibited comparable efficacy to niacin in reversing the lipolytic effect of isoproterenol, although its intrinsic potency was slightly lower.
Neither GPR109 receptor agonist-1 nor niacin showed any affinity for the β-adrenergic receptor.
Chemical Information
-
CAS No. 306935-41-1
-
Appearance Solid
-
Molecular Weight 205.22
-
Formula C10H11N3O2
-
Color Off-white to light yellow
-
SMILES
O=C(C1=CC=C(N(C(C)C)N=N2)C2=C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (487.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (291 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.8728 mL | 24.3641 mL | 48.7282 mL | 121.8205 mL |
| 5 mM | 0.9746 mL | 4.8728 mL | 9.7456 mL | 24.3641 mL | |
| 10 mM | 0.4873 mL | 2.4364 mL | 4.8728 mL | 12.1820 mL | |
| 15 mM | 0.3249 mL | 1.6243 mL | 3.2485 mL | 8.1214 mL | |
| 20 mM | 0.2436 mL | 1.2182 mL | 2.4364 mL | 6.0910 mL | |
| 25 mM | 0.1949 mL | 0.9746 mL | 1.9491 mL | 4.8728 mL | |
| 30 mM | 0.1624 mL | 0.8121 mL | 1.6243 mL | 4.0607 mL | |
| 40 mM | 0.1218 mL | 0.6091 mL | 1.2182 mL | 3.0455 mL | |
| 50 mM | 0.0975 mL | 0.4873 mL | 0.9746 mL | 2.4364 mL | |
| 60 mM | 0.0812 mL | 0.4061 mL | 0.8121 mL | 2.0303 mL | |
| 80 mM | 0.0609 mL | 0.3046 mL | 0.6091 mL | 1.5228 mL | |
| 100 mM | 0.0487 mL | 0.2436 mL | 0.4873 mL | 1.2182 mL |